Differential expression of SHP-1 in chronic myeloid leukemia

Despite the unprecedented success of tyrosine kinase inhibitors (TKIs), the clinical management of 20–30% of patients with chronic myeloid leukemia (CML) experiencing primary or secondary resistanc...